FLUOROSCOPY ELIMINATION

RESEARCH REVIEW

State of Fluoroless Procedures in Cardiac Electrophysiology Practice

UGUR CANPOLAT, MD,1,2 MICHELA FAGGIONI, MD,3 DOMENICO G. DELLA ROCCA, MD,1 QIONG CHEN, MD,1,4 HUSEYIN AYHAN, MD,1,5 ANDREW A. VU, MD,1,6 SANGHAMITRA MOHANTY, MD,1 CHINTAN TRIVEDI, MD,1 CAROLA GIANNI, MD,1 MOHAMMED BASSIOUNY, MD,1 AMIN AL-AHMAD, MD,1 J. DAVID BURKHARDT, MD,1 JAVIER E. SANCHEZ, MD,1 G. JOSEPH GALLINGHOUSE, MD,1 ANDREA NATALE, MD,1,7–10 and RODNEY P. HORTON, MD1,11,12

1Texas Cardiac Arrhythmia Institute, St. David's Medical Center, Austin, TX, USA
2Arrhythmia and Electrophysiology Unit, Department of Cardiology, Hacettepe University, Ankara, Turkey
3James J. Peters Veterans Affairs Medical Center, Bronx, NY, USA
4Henan Provincial People's Hospital, Zhengzhou, Henan, China
5Department of Cardiology, Ankara Yildirim Beyazit, Ankara, Turkey
6Department of Cardiology, California Pacific Medical Center, San Francisco, CA, USA
7Interventional Electrophysiology, Scripps Clinic, La Jolla, CA, USA
8Department of Cardiology, MetroHealth Medical Center, Case Western Reserve, University School of Medicine, Cleveland, OH, USA
9Division of Cardiology, Stanford University, Stanford, CA, USA
10Dell Medical School, University of Texas, Austin, TX, USA
11Department of Biomedical Engineering, Cockrell School of Engineering, University of Texas, Austin, TX, USA
12Division of Cardiology, Department of Medicine, University of Texas Health Sciences Center, San Antonio, TX, USA

ABSTRACT. In the past decade, the use of interventional electrophysiological (EP) procedures for the diagnosis and treatment of cardiac arrhythmias has exponentially increased. These procedures usually require fluoroscopy to guide the advancement and frequent repositioning of intracardiac catheters, resulting in both the patient and the operator being subjected to a considerable degree of radiation exposure. Although shielding options such as lead gowns, glasses, and pull-down shields are useful for protecting the operator, they do not lessen the patient’s level of exposure. Furthermore, the prolonged use of lead gowns can exacerbate the onset of orthopedic problems among operators. Recent advancements in three-dimensional cardiac mapping systems and the use of radiation-free imaging technologies such as magnetic resonance imaging and intracardiac ultrasound allow operators to perform EP procedures with minimal or even no fluoroscopy. In this review, we sought to describe the state of fluoroless procedures in EP practice.

KEYWORDS. Catheter ablation, electrophysiological study, fluoroscopy, imaging.

Introduction

Interventional electrophysiological (EP) procedures are widely used for both the diagnosis and treatment of various types of cardiac arrhythmias. These procedures require the use of intracardiac catheters, which are typically advanced and frequently repositioned under fluoroscopy guidance (conventional approach). Procedural and, more notably, fluoroscopic times have progressively lengthened because of the increasing complexity of EP procedures requiring detailed mapping and/or extensive ablation therapy. Therefore, significant efforts have been made in the past few years to reduce radiation exposure among both patients and operators alike. For instance,
the incorporation of advanced imaging modalities such as real-time ultrasonography (US), intracardiac echocardiography (ICE), and three-dimensional electroanatomic mapping (EAM) systems have greatly reduced the requirements for fluoroscopy in EP laboratories without any significant difference observed in the safety and efficacy of the procedures.\(^1\) Although all interventional EP centers should aim for fluoroscopy use to be as low as reasonably achievable (per the ALARA principle), variability in fluoroscopy times can be observed among centers as well as within the same center depending in part on procedure complexity and operator expertise.\(^4\) In a previous meta-analysis, Yang et al.\(^5\) demonstrated that there was no significant difference between minimal or zero fluoroscopy and conventional ablation with regard to procedural time, acute and long-term success rates, complications, and recurrence rates.

In order to implement minimal- or zero-fluoroscopy techniques in routine daily practice, physicians should be trained to use EAM systems and advanced intraoperative imaging modalities as early as possible—for example, either during their initial EP training or in supplementary hands-on courses. One of the drawbacks of this approach is the potential necessity of rescue fluoroscopy during emergent conditions while the operators and other laboratory staff are not wearing the appropriate lead protection.\(^6\) In the last decade, there has been a significant increase in the number of EP procedures performed with minimal or zero fluoroscopy.\(^1,7-9\) Any type of cardiac arrhythmia, including supraventricular tachycardias (SVTs), atrial fibrillation (AF), and ventricular arrhythmias (VAs), can in theory be ablated with a fluoroless approach in experienced centers. These fluoroless procedures are exceedingly significant in specific patient subpopulations who are at a higher risk of adverse effects from radiation exposure such as pregnant women, patients with obesity, and pediatric patients.\(^7,8,10-15\) In this review, we sought to describe how fluoroless procedures are carried out and highlight the new tools available to EP operators in this area of practice. In addition, we present the most recent data on fluoroless procedure outcomes.

Supportive imaging tools during fluoroless procedures

Many operators are used to relying heavily on fluoroscopic guidance during catheter manipulations. This constitutes a significant barrier to the successful implementation of the fluoroless approach wherein alternative nonradiographic imaging tools are utilized instead of fluoroscopy. For instance, at the beginning of the procedure, real-time ultrasound can be used to obtain jugular or femoral venous access in order to reduce access site complications. Next, two-dimensional phased-array intracardiac echocardiography (CARTO Sound; Biosense Webster Inc., Diamond Bar, CA, USA), three-dimensional ICE-based imaging, fast anatomical mapping (FAM) or EAM systems, and medical positioning systems (MediGuide, Inc., Wilmington, DE, USA) are used separately or in conjunction with one another as necessary based on the type of procedure and preference of the operator.\(^1,2,6-8,16-18\) Preprocedural segmented computerized tomography (CT) or magnetic resonance imaging (MRI) can be integrated with EAM systems to limit fluoroscopy use. In a limited number of cases, fluoroless catheter ablations guided by three-dimensional transesophageal echocardiography (TEE) have been reported, including for typical atrial flutter (AFL), AF, accessory pathway, and ischemic ventricular tachycardia (VT) ablation.\(^19,20\) These imaging tools are used to visualize the anatomy of the cardiac chambers of interest and, in the case of the EAM, can also be used to study the electrical activity within the cavity in order to better guide the ablation procedure. Visualization of the chambers’ anatomy is helpful to understand the exact location of the catheter with respect to the chamber wall. Diagnostic catheters can be appropriately positioned in standard locations simply with the help of ICE, CT/MRI, medical positioning system, or EAM system annotations made on anatomical images. Overall, these tools can increase operators’ confidence regarding the safety of the procedure.

It has been suggested that a fluoroless approach may prolong the duration of the procedure. Although this may be true during the initial learning phase, prospective comparisons do not support this notion.\(^17\) Finally, in some specific conditions such as when treating patients with pacemaker/implantable cardioverter-defibrillator leads, interatrial septal defect closure devices, complex anatomic variations, or poor resolution achieved with fluoroless imaging tools, minimal fluoroscopy may be required to safely complete the procedure.\(^2\) Therefore, these procedures may be categorized as minimal- or zero-fluoroscopy based on specific needs.

State of fluoroless procedures for supraventricular tachyarrhythmias

Most of the fluoroless procedures reported in the literature represent single-center experiences involving patients with right-sided supraventricular tachyarrhythmias such as atrioventricular nodal reentrant tachycardia (AVNRT), accessory pathways, typical/atypical AFL, and right atrial tachycardia (AT).\(^12,14,16-18\) (Table 1). Less frequently shared are reports of fluoroless ablations of AF (Table 2) left-sided atrial tachyarrhythmias, and VAs (Table 3). Although many operators are now experienced in the use of ICE for cardiac ablations, there are technical difficulties in the visualization of left atrial or left ventricular structures from the standard right atrial location of the ICE catheter. This

---

Dr. Burkhardt is a consultant for Biosense Webster and Stereotaxis. Dr. Natale has received speaker honoraria from Boston Scientific, Biosense Webster, St. Jude Medical, Biotronik, and Medtronic and is a consultant for Biosense Webster, St. Jude Medical, and Janssen. All other authors have no conflicts of interest for the published content. Manuscript received April 15, 2019. Final version accepted May 28, 2019.

Address correspondence to: Domenico G. Della Rocca, MD, 3000 North Interstate Highway 35, Suite 700, Austin, TX 78705, USA. Email: domenicodellarocca@hotmail.it.
| Study               | No. of Fluoroless Patient(s) | Arrhythmia Type(s)                          | Imaging Modality | Procedural Time | Fluoroscopy Time for Study Group | Follow-up Success Rate(s) | Complication Rate(s) |
|--------------------|-----------------------------|---------------------------------------------|------------------|----------------|----------------------------------|--------------------------|----------------------|
| Scaglione et al.7  | 44                          | Concealed accessory pathway                 | EAM              | 94.4 ± 4.4 min | 100% zero fluoroscopy            | 84.1% at 16.0 ± 11.7 months | 0%                   |
| Walsh et al.9      | 50                          | AVNRT, AFL, accessory pathway, AT, AV-node ablation | EAM              | 57 min         | 100% zero fluoroscopy            | 98% at 4.9 months         | 0%                   |
| Ozturk et al.11    | 9                           | Mahaim pathways                            | EAM              | 249 ± 90 min   | 4.5 min, 66.7% zero fluoroscopy  | 77.8% at 25 months         | 0%                   |
| Elkiran et al.12   | 39                          | AT                                          | EAM, fluoroscopy | 184.23 ± 60.19 min | 5.53 ± 5.22 min, 64.1% zero fluoroscopy | 87.2% at 51.35 ± 12.62 months | 2.5%               |
| Drago et al.22     | 21                          | Right-sided accessory pathway/ WPW          | EAM, fluoroscopy | NA             | 9.2 ± 7.7 min in 12 patients, 42.8% zero fluoroscopy | 100% at 15 ± 7 months | 0%                   |
| Smith et al.23     | 30                          | AVNRT, AVRT                                | EAM, fluoroscopy | 3.27 hours     | 1.05 ± 2.9 min, 80% zero fluoroscopy | 87% at 3 months | Transient AV block in 30%         |
| Clark et al.24     | 10                          | Left-sided accessory pathway               | EAM, TEE, fluoroscopy | 266 min       | 100% zero fluoroscopy            | 10% at 6 months | 0%                   |
| Scaglione et al.25 | 21                          | AVNRT                                      | EAM, fluoroscopy | 70 ± 20 min    | 45 s and 50 s, 90.4% zero fluoroscopy | 76.2% at 25 months | 0%                   |
| Bigelow et al.26   | 2 neonates                  | WPW                                        | EAM              | 112 min and 110 min | 100% zero fluoroscopy            | 100% at 14 months and 7 months | 0%                |
| Alvarez et al.27   | 50                          | AVNRT                                      | EAM, fluoroscopy | 152 ± 35 min   | 98% zero fluoroscopy             | 96% in EAM group at 6 months | 2%                |
| Alvarez et al.28   | 83                          | Typical AFL                                | EAM, fluoroscopy | 141 ± 47 min   | 90.4% zero fluoroscopy           | 96.25% at 18 ± 12 months | 6%                   |
| Sommer et al.29    | 24                          | AVNRT, AVRT, WPW, AT, Typical AFL          | EAM, MediGuide, fluoroscopy | 70 ± 25 min | 0.5 ± 1.5 min | 100% (acute) | 0%                   |
| Jan et al.30       | 43                          | AVNRT, AT, AVRT, accessory pathway         | EAM, ICE, fluoroscopy | 126 ± 53 min | 100% zero fluoroscopy | 90.3% at 10 ± 3 months | 0%                |
| Ruiz-Granell et al.34 | 1                          | AV-node ablation + pacemaker implantation | EAM              | 87 min         | < 1 min                          | 100%                     | 0%                   |
| Gist et al.36      | 62                          | AVNRT                                      | EAM              | 202 ± 76 min in early vs. 160 ± 61 min in recent era | 88.7% at 12 months | Transient AV block in 44% in early vs. 38% in recent era | 0%                |
| Stec et al.37      | 188                         | AVNRT, AVRT, WPW, AFL, AT, double tachycardia | EAM, fluoroscopy | 63 ± 26 min   | 95.2% zero fluoroscopy           | 93.5% at 8.0 ± 5.2 months | 0%                   |
| Fernandez-Gomez et al.38 | 328 | AVNRT, AVRT, Typical AFL, incisional AFL, AT | EAM, fluoroscopy | 110.5 ± 51.8 min | 94.7% zero fluoroscopy | 96.5% at 6 months | 0.3%               |
| Ceresnak et al.39  | 651                         | Accessory pathway, WPW                     | EAM, fluoroscopy | NA             | 100% zero fluoroscopy            | 95% at 1.0 ± 0.9 years | 0.3%               |
### Table 1: Continued

| Study                | No. of Fluoroless Patient(s) | Arrhythmia Type(s)                          | Imaging Modality | Procedural Time | Fluoroscopy Time for Study Group | Follow-up Success Rate(s) | Complication Rate(s) |
|----------------------|------------------------------|---------------------------------------------|------------------|-----------------|----------------------------------|--------------------------|----------------------|
| Giaccardi et al.     | 297                          | AVNRT, AFL, accessory pathway               | EAM, fluoroscopy | 87 ± 57 min     | 14 s ± 6 s, 86% zero fluoroscopy  | 98% (acute)              | 2.1%                 |
| Casella et al.       | 134                          | AVNRT, accessory pathway, AFL, AT           | EAM, fluoroscopy | NA              | 0–12 s, 72% zero fluoroscopy     | 97% at 12 ± 4 months    | 0%                   |

AF: atrial fibrillation, AFL: atrial flutter, AT: atrial tachycardia, AV: atrioventricular, AVNRT: atrioventricular nodal reentrant tachycardia, AVRT: atrioventricular reentrant tachycardia, EAM: electroanatomic mapping, ICE: intracardiac echocardiography, NA: not applicable, PJRT: permanent junctional reciprocating tachycardia, VPC: ventricular premature contraction, WPW: Wolf–Parkinson–White syndrome.

### Table 2: Studies Including AF Patients in Whom Near-zero- or Zero-fluoroscopy Catheter Ablation Was Performed

| Study                | No. of Fluoroless Patient(s) | Arrhythmia Type(s) | Imaging Modality          | Procedural Time | Fluoroscopy Time for Study Group | Follow-up Success Rate(s)                        | Complication Rate(s) |
|----------------------|------------------------------|--------------------|----------------------------|-----------------|----------------------------------|-------------------------------------------------|----------------------|
| Percell et al.       | 72                           | AF                 | EAM, ICE                   | 210.38 min      | 0.1 min                           | 68% at 3 months                                  | 5%                   |
| Bulava et al.        | 40                           | AF                 | EAM, ICE                   | 92.5 ± 22.9 min | 8 s, 97.5% zero fluoroscopy      | 85% at 12 months                                 | 0%                   |
| Yamada et al.        | 15                           | AF                 | EAM, CT, MediGuide™        | NA              | NA                               | 82% at 12.2 ± 4.5 months                        | 0%                   |
| Rolf et al.          | 80                           | AF                 | EAM, MediGuide™, fluoroscopy | 167 ± 47 min    | 4.6 min                           | NA                                              | 4% minor             |
| Sommer et al.        | 1000                         | AF                 | EAM, MediGuide™, fluoroscopy | 120 min         | 0.9 min                           | NA                                              | 2%                   |
| Reddy et al.         | 20                           | AF                 | EAM, ICE, fluoroscopy      | 244 ± 75 min    | 244 ± 75 min                      | 90% at 6.1 ± 2.2 months                         | 0%                   |
| Lyan et al.          | 245                          | AF                 | EAM, ICE, fluoroscopy      | 108.8 ± 18.2 min| 35, 44, and 107 s, 98.8% zero fluoroscopy | 73.5% at 15.2 ± 4.1 months                     | 1.2% cardiac tamponade in the no-fluoroscopy group |
| Ferguson et al.      | 22                           | AF                 | EAM, ICE, fluoroscopy      | 208 min         | 2–16 min, 86.3% zero fluoroscopy  | 76% at 7 months                                 | 0%                   |
| O’Brien et al.       | 69                           | AF                 | EAM, TEE, fluoroscopy      | 124.04 ± 45.41 min| 54% (development phase) vs. 93.3% (implementation phase) zero fluoroscopy | NA                                              | 4.3%                 |
| Liu et al.           | 200                          | AF                 | EAM, ICE                   | 106.2 ± 23.2 min| 100% zero fluoroscopy            | 76% at 11 months                                 | 1%                   |

AF: atrial fibrillation, CT: computed tomography, EAM: electroanatomic mapping, ICE: intracardiac echocardiography, NA: not applicable, TEE: transesophageal echocardiography.
limits the routine use of ICE in guiding left-sided ablation procedures. There have been several papers published on the role of three-dimensional EAM and/or other imaging tools to reduce fluoroscopy use during SVT ablations. However, these usually involve the reduced or minimal use of fluoroscopy, with reports of zero-fluoroscopy procedures remaining scarce. Children and newborns are a special subpopulation with a higher lifelong cumulative risk of radiation-related morbidity given their longer life expectancy as compared with adults. In these very young patients, minimal or zero-fluoroscopy approaches, usually with the use of three-dimensional EAM and ICE, have been implemented earlier and more rapidly than in adult patients. This was possible because most of the cardiac arrhythmias observed in children are SVT with a right-side origin (> 90% of cases are AVNRT), which can be easily treated with fluoroless procedures. Herein, we discuss the current state of fluoroless approaches in SVTs including AVNRT, accessory pathways, AFL, and ATs among pediatric and adult populations.

Ruiz-Granell et al. was one of the first study groups to report on the use of an uncomplicated, zero-fluoroscopy approach involving EAM during atrioventricular node ablation and permanent pacemaker implantation. Shortly thereafter, Earley et al. showed that the involvement of three-dimensional EAM systems significantly reduced procedural and fluoroscopy times in a variety of conditions requiring ablation including AVNRT, AVRT, AFL, and VT, with similar resulting success and complications rates as compared with those associated with the conventional approach. Specifically, the median radiation exposure was four minutes (range: 0–50 minutes) in the EAM-guided strategy group and 13 minutes (range: 12–46 minutes) in the conventional strategy group.

Elsewhere, Gist et al. described their learning curve over time during the transition to fluoroless ablations of AVNRT. In their study, 62 consecutive patients who underwent fluoroless cryoablation of AVNRT between December 2005 and August 2008 were included. The first 12 months since technique introduction were considered the “early era” (December 2005–December 2006; n = 27), whereas the “recent era” included the following 20 months (January 2007–August 2008; n = 35). Although no significant procedural complications were reported regardless of the “era,” a significant reduction in procedural time was observed over time [early era: 202 (100–419) minutes versus recent era: 160 (78–332) minutes]. The recurrence rates were 15% in the early era and 8% in the recent era, respectively.

Data from a multicenter prospective catheter ablation registry including both children and adults were presented by Stec et al., where 179 out of 188 procedures were performed without fluoroscopy. Among these procedures, an acute success rate of 98% and a long-term success rate of 93% were achieved without major complications; these results were similar to those in the fluoroscopy-guided control group. Further, Fernandez-Gomez et al. demonstrated that a fluoroless approach using the EnSite™ NavX™ system (Abbott Laboratories, Chicago, IL, USA) was feasible, safe, and effective in a total of 340 procedures, including 153 typical AFL, 146 AVNRT, 35 AVRT, four incisional AFL, and two focal AT cases, respectively, during a six-year period. The authors additionally reported a high acute success rate (99.1%) with zero fluoroscopy applied in 94.7% of the procedures and a mean procedural duration of 110.5 minutes ± 51.18 minutes.

Of note, a multicenter study has shown a higher success rate of three-dimensional EAM-guided procedures as compared with procedures directed by fluoroscopy alone (97% versus 91%) for the ablation of accessory pathways in a pediatric population, with no significant difference in recurrence (5% versus 9%) or complication rates (0.3% versus 0.4%). In another multicenter study including 442 consecutive adult patients with SVT (43% AVNRT; 35% right-sided AFL; 11% accessory pathway; and 11% AT, atypical AFL, or VT), Giaccardi et al. also demonstrated the efficacy (acute success rate of 96% versus 97%) and safety (complication rate of 4.4% versus 2.1%) of near-zero fluoroscopy with the aid of the EnSite™ Velocity™ system (Abbott Laboratories, Chicago,

---

### Table 3: Studies Including VA Patients in Whom Near-zero- or Zero-fluoroscopy Catheter Ablation Was Performed

| Study          | No. of Fluoroless Patient(s) | Arrhythmia Type(s)                  | Imaging Modality | Procedural Time (min) | Fluoroscopy Time for Study Group | Follow-up Success Rate(s) | Complication Rate(s) |
|---------------|-------------------------------|------------------------------------|------------------|-----------------------|-------------------------------|--------------------------|----------------------|
| Akdeniz et al. | 35                            | VAs                                | EAM, fluoroscopy | 175 ± 67              | 2.35 ± 1.89 min, 54.3% zero fluoroscopy | 80% at 15.9 ± 7.1 months | 8.6%                 |
| Ozyilmaz et al. | 17                           | VTs                                | EAM              | 169.3 ± 43.2 min      | 8.6 ± 10.8 min, 35.3% zero fluoroscopy | 82.4% at 8.5 ± 7.6 months | 5.9%                 |
| Cano et al.    | 41                            | VT (endo- and/or epicardial)        | EAM, CARTO-UNIVU Module, fluoroscopy | 193 ± 62 min for ischemic VT, 217 ± 59 min for nonischemic VT | 6.08 min, 32% zero fluoroscopy | 92.7% at 217 days | 4.9%                 |
| Wang et al.    | 163                           | VAs                                | EAM              | 77.1 ± 33.8 min       | 94.4% zero fluoroscopy | 88.1% at 5.4 ± 3.9 months | 0.6% major            |

EAM: electroanatomic mapping, VA: ventricular arrhythmia, VT: ventricular tachycardia.
IL, USA) in comparison with the conventional approach, without a significant increase in procedural duration (91 ± 52 minutes versus 87 ± 57 minutes). Importantly, 14% of the patients required rescue fluoroscopy because of difficult venous access, need to confirm catheter stability and location, frequent coronary sinus (CS) catheter dislocation, problems with the EAM system, and a need to check the positioning of guidewires. In 2019, the same group reported their long-term outcomes with a fluoroless approach over six years of experience.41

In the Radiation Exposure Reduction in SVT Ablation (NO-PARTY) study,42 a total of 262 patients undergoing EP study for supraventricular tachycardia (no AF) were randomized to a minimal fluoroscopic approach with the EnSiteTM NavX™ navigation system (Abbott Laboratories, Chicago, IL, USA) or to a conventional approach procedure. The study results clearly showed similar degrees of safety and efficacy for both approaches with no radiation exposure in the minimal fluoroscopic approach group.

After demonstrating the feasibility, safety, and efficacy of fluoroless catheter ablation in 60 patients,43 Razminia et al.1 presented their five-year fluoroless catheter ablation experience in 500 consecutive patients with various types of cardiac arrhythmias (n = 639 arrhythmias) including AVNRT (n = 31), AVRT (n = 79), macro-AT (n = 188), focal AT (n = 111), AF (n = 186), VT (n = 14), and ventricular premature contractions (VPCs) (n = 30). The procedures were performed primarily using ICE and three-dimensional EAM guidance. Although there were no major complications in the AVRT, AVNRT, VT, and macro-AT patients, major complication rates of 1.7% in focal AT, 1.6% in AF, and 3.3% in VPC patients, respectively, were reported. No death events were reported in any patient group. Success rates were also consistent with previously published findings within each cardiac arrhythmia type. The mean procedural duration was significantly reduced over the years from 209.6 minutes in 2011 to 114.2 minutes in 2016.

State of fluoroless procedures for atrial fibrillation

The fluoroless approach is less common in AF ablation procedures in comparison with SVT ablations (Tables 1 and 2). This may be in part due to the technical limitations of current imaging modalities to appropriately visualize left-sided structures as well as the greater complexity inherent in performing left-sided ablation procedures even when using the conventional approach.2 Moreover, operators are often more confident when performing certain maneuvers under fluoroscopic guidance such as the pull-back of transseptal sheaths in patients with intracardiac pacemaker/implantable cardioverter-defibrillator leads or transseptal puncturing in difficult anatomies. However, exposure to ionizing radiation in the fluoroscopic approach is higher in AF ablation as compared with the ablation of other supraventricular tachyarrhythmias.4 Therefore, the implementation of near-zero or zero fluoroscopy in AF ablation procedures would be critical to reduce the degree of radiation exposure for both patients and operators. Depending on the availability and operator’s experience with different noninvasive imaging tools such as two- and three-dimensional ICE, three-dimensional TEE, EAM, CT, or MRI segmentation and integration, ablations can be performed for the treatment of AF without using fluoroscopy. A simple two-dimensional ICE approach can assess intracardiac structures, guide a transseptal puncture, evaluate the distance between the catheter tip and the wall contact, and assess for procedural complications such as pericardial effusion. Operators mainly focus on the transseptal puncture as a critical and rate-limiting step in fluoroless AF ablation. However, there are alternative techniques available depending upon the experiences of the operators that are able to reduce fluoroscopy during transseptal puncture. In summary, these include, after positioning the ICE catheter in the right atrium, obtaining sound contours from the aortic root, the ostium of the CS, and the fossa ovalis; limited FAM of the CS, superior vena cava (SVC), and interatrial septum; positioning of the CS catheter; placement of the long-wire in the SVC per the guidance of ICE; advancement of the transseptal sheath and dilator over this wire by observing them in the SVC using ICE images; conducting advancement of a blunt transseptal needle (Baylis Medical, Toronto, Ontario, Canada) via a transseptal sheath; visualizing the uncovered needle tip on the mapping system; and performing withdrawal of the needle and sheath until the needle tip is in the desired area of the fossa ovalis on ICE and RF energy can be delivered to cross the septum (Figure 1).45

In 2013, the Leipzig group reported their experience using MediGuide™ technology as a nonfluoroscopic imaging tool (MediGuide, Inc., Wilmington, DE, USA) for AF ablation procedures in 80 patients. The total procedural time was 167 minutes ± 47 minutes, with a median of 4.6 minutes of fluoroscopy to complete background loops, transseptal puncture, confirmation of the transseptal sheath position, and manipulation of the circular mapping catheter. Ultimately, in this patient cohort, there were only three (4%) minor complications.46 Elsewhere, Sommer et al.47 reported their large-volume experience with MediGuide™ four-dimensional navigation technology (MediGuide, Inc., Wilmington, DE, USA) including 1,000 patients who underwent AF ablation between 2012 and 2017, where the median fluoroscopy time was 0.9 minutes ± 2.7 minutes, with an acceptable complication rate of 2%.48 Completely fluoroless procedures were performed by Razminia et al.1 on 500 patients with supraventricular tachycardia, AF, premature ventricular complexes, and VT. Thanks to the supportive role of ICE, EAM, and intracardiac electrograms, an acceptable success rate was achieved with similar procedural duration times as compared with those of the conventional approach. The risk of complications also remained unchanged.

Small case series evaluating fluoroless approaches for the ablation of paroxysmal AF have also been reported.17,49–52 In 245 patients with paroxysmal AF, Lyan et al.50 reported
that the fluoroless approach had similar procedural times as compared with fluoroscopy-guided ablations (108.8 ± 18.2 minutes in the fluoroless group versus 113.6 ± 26.8 minutes in the fluoroscopy-guided group). Three of 245 patients (1.2%) in the fluoroless group developed cardiac tamponade and required rescue fluoroscopy during pericardiocentesis.

In a retrospective analysis of five years of experience including 186 AF patients (including 150 treated with radiofrequency and 36 treated with cryoballoon), Razminia et al. reported the achievement of a total of 194 minutes of procedural time, a 1.6% rate of major complications (two cases of cardiac tamponade and one case of atrioesophageal fistula), and a 22.6% rate of recurrence.

Different from other patient series, O’Brien et al. reported their experience with a fluoroless approach using three-dimensional EAM and TEE rather than ICE in a total of 55 AF patients. The total procedural time was similar to that in the fluoroscopic approach group used as a control population and was consistent with previous series performed using ICE instead of TEE. The complication rate was also acceptable.

Liu et al. performed AF ablation in a total of 200 consecutive patients (AFL and nonpulmonary-vein triggers in 82% and paroxysmal AF in 55%) by using ICE, a non-navigation circular catheter, and contact force-sensing ablation catheters without anatomic mapping. The mean procedural time was 106.2 minutes ± 23.2 minutes, with a success rate of 76% at a median follow-up of 11 months. The complication rate was low (1% for minor complications) and the novel approach was cost-saving (ICE and circular mapping catheters were reprocessed). Furthermore, there were no adverse events related to the intracardiac leads in 19 of 200 patients with intracardiac devices.

Sadek et al. more recently published their experience with a fluoroless approach in a relatively complex patient population including 70 complex left AT (33 with persistent AF and six with left AFL) and 10 VT (60% with scar-mediated VT) ablations performed using ICE and EAM guidance, which had a 100% acute success rate, similar procedural times as compared with when using fluoroscopic guidance, and no complications. Despite such a limitation, the authors added to the evidence regarding the feasibility of a fluoroless approach in complex cardiac arrhythmias, including a more complex atrial substrate and a higher burden of atrial scar, characteristics which require more extensive ablation as compared with standard pulmonary vein isolation.

State of fluoroless procedures for ventricular arrhythmias

Although the fluoroless approach has been frequently deployed in both children and adults with SVTs, its use in patients with VAs has so far been limited (Table 3). This can be attributed to various reasons including limitations of supportive imaging tools for the study of ventricular anatomy, complexity of ventricular anatomy, limited experience of the operators, presence of intracardiac devices with the risk of lead dislocation, and difficulty in left ventricular access via both retrograde or antegrade approaches. Nevertheless, the use of a fluoroless approach for the ablation of VAs is destined to grow due to the increasing number of patients requiring ventricular ablations and the improvement of advanced imaging technologies for the visualization of ventricular components and neighboring structures. Similar to the procedure for SVT, the fluoroless approach in patients with VA is based on advanced imaging tools like ICE, three-dimensional EAM, and the integration of CT or MRI segmentation such as the CartoUnivu™ Module (Biosense Webster, Diamond Bar, CA, USA). With implementation of these imaging tools, fluoroless procedures have been successfully performed in idiopathic VT case series, with similar procedural efficacy rates and durations as compared with those achieved using a fluoroscopic approach. Notably, 5% to 6% of patients initially treated with the fluoroless approach still required rescue fluoroscopy.

As mentioned in a previous section, Sanchez et al. reported their single-center experience with a fluoroless
approach using three-dimensional EAM in all patients and ICE in 70.4% of patients. The study included a total of 10 ablation procedures for VAs including VPCs and VTs with a mean procedure time of 150 minutes ± 45 minutes and no complications. Furthermore, Sadek et al.\(^5\) reported a total of 10 fluoroless VT ablations (60% involving scar-mediated VTs and 1% being ARVC-mediated) using ICE and three-dimensional EAM. All patients with outflow-tract VPCs demonstrated no recurrence during follow-up, and the treatment success rate was 83% in patients with scar-mediated VTs. As most of these patients have intracardiac devices, operators should be careful not to dislodge the leads during catheter insertion or during transseptal access. The leads should be carefully visualized before and just after the ablation procedure to confirm the positioning of the leads.

State of fluoroless procedures for special populations

As previously mentioned, fluoroless catheter ablation procedures are particularly important when it comes to specific patient subgroups such as children, pregnant women (Table 4), or patients with obesity. In pregnant women, the avoidance of radiation exposure is especially critical during the first trimester of pregnancy because of the higher risk for fetal adverse effects. Therefore, the risks and benefits of catheter ablation procedures in these subpopulations should be carefully evaluated by the treating physicians. If catheter ablation is planned, operators should strongly consider using a fluoroless approach.

Although there are several single-center or multicenter studies available that describe the feasibility, safety, and efficacy of fluoroless procedures in children, data on pregnant women are available from just a few case reports and case series. Nevertheless, data in pregnant women diagnosed with SVTs such as AVNRT, AVRT, PJRT, AT, AF, or ventricular arrhythmias including VPCs and/or VTs seem to support the performance of fluoroless three-dimensional EAM- or ICE-guided procedures in between 10 weeks and 38 weeks of pregnancy without any associated complications for the patient or the baby. Procedural times were consistent with previous reports on nonpregnant patients undergoing the same procedure.\(^5\)\(^6\) The ablation of ventricular arrhythmias in two pregnant patients, one with idiopathic right ventricular outflow-tract (RVOT) VPC and the other with VT (RVOT anterior) due to electrical storm in ARVC, were also successfully performed with the use of three-dimensional EAM.

State of reduced fluoroscopy during cardiac implantable electronic device placement

Imaging of the venous puncture site, wire, and lead placement location is necessary during cardiac implantable electronic device (CIED) implantations, and fluoroscopy remains by far the most commonly

### Table 4: Procedural and Follow-up Details of Pregnant Women with Different Types of Arrhythmias in Whom Near-zero- or Zero-fluoroscopy Catheter Ablation Was Performed

| Study | Imaging Modality | Procedure Time | Procedural and Follow-up Details of Pregnant Women with Different Types of Arrhythmias |
|-------|------------------|----------------|------------------------------------------------------------------------------------------------|
| - | ICE | 55±18 min | 1 pregnant (19th–23rd week) |
| - | EAM, fluoroscopy | 100% zero fluoroscopy | 1 pregnant (16th–20th week) |
| - | EAM, ICE | 100% zero fluoroscopy | 1 pregnant (22nd–26th week) |
| - | NA | 100% zero fluoroscopy | 1 pregnant (27th–31st week) |
| - | NA | 100% zero fluoroscopy | 1 pregnant (32nd–36th week) |
| - | NA | 100% zero fluoroscopy | 1 pregnant (37th–41st week) |
| - | NA | 100% zero fluoroscopy | 1 pregnant (42nd–45th week) |
| - | NA | 100% zero fluoroscopy | 1 pregnant (46th–50th week) |
| - | NA | 100% zero fluoroscopy | 1 pregnant (51st–53rd week) |
| - | NA | 100% zero fluoroscopy | 1 pregnant (54th–58th week) |
| - | NA | 100% zero fluoroscopy | 1 pregnant (59th–63rd week) |
| - | NA | 100% zero fluoroscopy | 1 pregnant (64th–68th week) |
| - | NA | 100% zero fluoroscopy | 1 pregnant (69th–73rd week) |

AF: atrial fibrillation, AT: atrial tachycardia, AVNRT: atrioventricular nodal reentrant tachycardia, AVRT: atrioventricular reentrant tachycardia, ARVC: arrhythmogenic right ventricular cardiomyopathy, EAM: electronic device placement, ICE: intracardiac echocardiography, NA: not applicable, PJRT: permanent junctional reciprocating.
| Study                  | No. of Fluoroless Patient(s) | Arrhythmia Type(s)          | Imaging Modality | Procedural Time | Fluoroscopy Time for Study Group | Follow-up Success Rate(s) | Complication Rate(s) |
|------------------------|-----------------------------|-----------------------------|------------------|----------------|-------------------------------|--------------------------|----------------------|
| Razminia et al.¹        | 500                         | AF, AVNRT, AVRT, AT, VAs    | EAM, ICE        | 194.4 min for AF | 0.3 min, 99.5% zero fluoroscopy | 77.3% for AF at 21.2 months; 78.6% for VT at 16.6 months | 1% major, 0.6% minor |
| Tuzcu et al.₈           | 183                         | AVNRT, AVRT, AT, Junctional tachycardia, VT | EAM, fluoroscopy | 202.8 ± 83.1 min | 63% zero fluoroscopy | 90% at 44.9 ± 23.3 months | 0.7% |
| Koca et al.₅₅           | 78                          | AVNRT, accessory pathway, AT, VAs | EAM, fluoroscopy | 153.1 ± 44.3 min | 5.4 ± 3.15 min, 81.6% zero fluoroscopy | 94.9% at 43.4 weeks ± 23.3 weeks | 2.5% |
| Sanchez et al.₃¹        | 107                         | SVT, AF, AFL, VAs           | EAM, ICE        | 26 ± 50 min     | 100% zero fluoroscopy | NA                      | 0% |
| Kozluk et al.₃₂         | 45                          | AVNRT, WPW, AT, VAs         | EAM, fluoroscopy | 110 ± 43 min    | 84% zero fluoroscopy | 89.5%                    | 2.2% minor |
| Kipp et al.₃₃           | 124                         | AVNRT, AVRT, AT, AFL, accessory pathways, VAs | EAM, fluoroscopy | NA               | 1.21 ± 1.18 min, 76% zero fluoroscopy | 91.9% overall | 3.81% minor |
| Earley et al.⁷₅         | 94                          | AVNRT, AVRT, AFL, Other (AT, VT) | EAM, fluoroscopy | 90 min | 6 min in CARTO and 4 min in NavX groups | 86% in CARTO and 87% in NavX groups at 6th week | 2% in CARTO and 2% in NavX groups |
| Giaccardi et al.⁴₆      | 266                         | AVNRT, AVRT, accessory pathway, AFL, AT, VAs, AV-node ablation, AF | EAM | 75 ± 0 min to 145 ± 15 min for different arrhythmias | 100% zero fluoroscopy | 90.8% at 2.9 ± 1.6 years | 0.8% |
| Razminia et al.₆¹        | 60                          | AF, AVNRT, AVRT, AFL, AT, VAs | EAM, ICE, fluoroscopy | NA | 100% zero fluoroscopy | NA | 1.6% minor |
| Haegeli et al.₃₂        | 34                          | AF, VAs, AVNRT, Typical AFL | EAM, ICE, fluoroscopy | 130 ± 50 min for AF | 54% for AF and 62% overall zero fluoroscopy | NA | 2.9% |
| Sadek et al.₅₅          | 80                          | AF, AFL, VAs                | EAM, ICE       | 225 ± 32 min    | 100% zero fluoroscopy | 91.2% at 18.1 ± 3.6 months | 0% |
| Wannagat et al.₇₂       | 57                          | AVNRT, AVRT, AT, AFL, VAs   | EAM             | 88.8 ± 31.4 min in no-TSP group, 131 ± 29.2 min in TSP group | 1.6 ± 4.2 min in no-TSP group, 3.2 ± 1.5 min in TSP group | 95.5% at 3 months in no-TSP group and 92.3% at 3 months in TSP group | 0% |

AF: atrial fibrillation, AFL: atrial flutter, AT: atrial tachycardia, AV: atrioventricular, AVNRT: atrioventricular nodal reentrant tachycardia, AVRT: atrioventricular reentrant tachycardia, EAM: electroanatomic mapping, ICE: intracardiac echocardiography, NA: not applicable, PJRT: permanent junctional reciprocating tachycardia, TSP: trans-septal puncture, VA: ventricular arrhythmia, VT: ventricular tachycardia, VPC: ventricular premature contraction, WPW: Wolf–Parkinson–White syndrome.
used approach, particularly for the insertion of cardiac resynchronization therapy devices. By involving ultrasonographic guidance during transvenous access and the placement of wires and sheaths as well as making simple modifications to modern X-ray system settings by way of further advancements in technology, the total radiation dose can be reduced significantly.69–71 As image quality demands are usually modest for most CIED implantations, the use of an ultralow frame rate (2–4 frames/s) and antiscatter gridless (removal of antiscatter grid setting) radiation protocols significantly reduce the radiation dose needed during the implantation of CIEDs without an increase in procedural duration or complication rates.71

Conclusions

“Near-zero” or “zero” fluoroscopic procedures that implement advanced imaging tools, including three-dimensional EAM and ICE, have been shown to be as safe and effective as the traditional fluoroscopy-guided approach. Fluoroless procedures not only avoid the unnecessary exposure of patients and health care providers to radiation but also limit the prolonged use of lead gowns, which results in a reduced incidence of musculoskeletal complications among operators. With adequate training, this approach can be safely and effectively implemented without any increase in procedural time. Nevertheless, “rescue” fluoroscopy should readily be made available at all times in the case of complications such as cardiac tamponade, difficulties with advancing or localizing catheters, or technical problems with the EAM systems or other imaging modalities. The fluoroless approach should be decidedly favored in selected subgroups including children, patients with obesity, and pregnant women in whom the effects of radiation exposure can be especially adverse and can be applied in the treatment of a variety of arrhythmia types (Table 5). Large studies will be necessary to further validate the fluoroless approach, particularly for the purpose of VT ablation.

References

1. Razminia M, Willoughby MC, Demo H, et al. Fluoroless catheter ablation of cardiac arrhythmias: a 5-year experience. Pacing Clin Electrophysiol. 2017;40(4):425–433.
2. Lerman BB, Markowitz SM, Liu CF, Thomas G, Ip JE, Cheung JW. Fluoroless catheter ablation of atrial fibrillation. Heart Rhythm. 2017;14(6):928–934.
3. Yamagata K, Wichterle D, Roubicek T, et al. Ultrasound-guided versus conventional femoral venipuncture for catheter ablation of atrial fibrillation: a multicentre randomized efficacy and safety trial (ULTRA-FAST trial). Europace. 2018;20(7):1107–1114.
4. Heidbuchel H, Wittkampf FH, Vano E, et al. Practical ways to reduce radiation dose for patients and staff during device implantations and electrophysiological procedures. Europace. 2014;16(7):946–964.
5. Yang L, Sun G, Chen X, et al. Meta-analysis of zero or near-zero fluoroscopy use during ablation of cardiac arrhythmias. Am J Cardiol. 2016;118(10):1511–1518.
6. Percell J, Sharpe E, Percell R. SANS FLUORO (SAy No Series to FLUORoscopy): a first-year experience. J Innov Card Rhythm Manage. 2016;7:25–29.
7. Scaglione M, Ebrille E, Caponi D, et al. Zero-fluoroscopy ablation of accessory pathways in children and adolescents: CARTOS3 Electroanatomic Mapping Combined with RF and Cryoenergy. Pacing Clin Electrophysiol. 2015;38(6):675–681.
8. Tuzcu V. Significant reduction of fluoroscopy in pediatric catheter ablation procedures: long-term experience from a single center. Pacing Clin Electrophysiol. 2012;35(9):1067–1073.
9. Walsh KA, Galvin J, Keaney J, Keelan E, Szeplaki G. First experience with zero-fluoroscopic ablation for supraventricular tachycardias using a novel impedance and magnetic-field-based mapping system. Clin Res Cardiol. 2018;107(7):578–585.
10. Tuzcu V. A nonfluoroscopic approach for electrophysiology and catheter ablation procedures using a three-dimensional navigation system. Pacing Clin Electrophysiol. 2007;30(4):519–525.
11. Ozturb E, Ergul Y, Tanidir IC, Akdeniz C, Tola HT, Tuzcu V. Electroanatomic mapping guided cryoablation of Mahaim pathways in children with limited fluoroscopy exposure. Pacing Clin Electrophysiol. 2015;38(3):362–367.
12. Elkirian O, Akdeniz C, Karacan M, Tuzcu V. Electroanatomic mapping-guided catheter ablation of atrial tachycardia in children with limited/zero fluoroscopy. Pacing Clin Electrophysiol. 2019;42(4):453–457.
13. Akdeniz C, Gul EE, Celik N, Karacan M, Tuzcu V. Catheter ablation of idiopathic right ventricular arrhythmias in children with limited fluoroscopy. J Inter Card Electrophysiol. 2016;46(3):355–360.
14. Orsildaz I, Ergul Y, Akdeniz C, Ozturk E, Tanidir IC, Tuzcu V. Catheter ablation of idiopathic ventricular tachycardia in children using the EnSite NavX system with/without fluoroscopy. Cardiol Young. 2014;24(5):886–892.
15. Koca S, Pac FA, Eris D, Zuban MM, Ozske O, Ozcan F. Electroanatomic mapping-guided pediatric catheter ablation with limited/zero fluoroscopy. Anatol J Cardiol. 2018;20(3):159–164.
16. Gaspar T, Kircher S, Arya A, et al. Enhancement of intra-cardiac navigation by new GPS-guided location system (MediGuide Technologies). Europace. 2012;14(Suppl 2):ii24–ii25.
17. Bulava A, Hanis J, Eisenberger M. Catheter ablation of atrial fibrillation using zero-fluoroscopy technique: a randomized trial. Pacing Clin Electrophysiol. 2015;38(7):797–806.
18. Yamada S, Lo LW, Lin YJ, et al. The accuracy and clinical applicability of a sensor based electromagnetic non-fluoroscopic catheter tracking system. Korean Circ J. 2019;49(1):84–96.
19. Faletra FF, Regoli F, Nucifora G, Auricchio A. Real-time, fluoroless, anatomic-guided catheter navigation by 3D TEE during ablation procedures. JACC Cardiovasc Imaging. 2011;4(2):203–206.
20. Regoli F, Faletra FF, Nucifora G, et al. Feasibility and acute efficacy of radiofrequency ablation of cavotricuspid isthmus-dependent atrial flutter guided by real-time 3D TEE. JACC Cardiovasc Imaging. 2011;4(7):716–726.
21. Gautam S. Fluoroless ablation: to do now, or to do later, that is the question. J Innov Card Rhythm Manage. 2016;7:2536–2537.
22. Drago F, Silvetti MS, Di Pino A, Grutter G, Bevilacqua M, Leibovich S. Exclusion of fluoroscopy during ablation treatment of right accessory pathway in children. J Cardiovasc Electrophysiol. 2002;13(8):778–782.
23. Smith G, Clark JM. Elimination of fluoroscopy use in a pediatric electrophysiology laboratory utilizing three-dimensional mapping. Pacing Clin Electrophysiol. 2007;30(4):510–518.
24. Clark J, Bockoven JR, Lane J, Patel CR, Smith G. Use of three-dimensional catheter guidance and trans-esophageal echocardiography to eliminate fluoroscopy in catheter ablation of left-sided accessory pathways. *Pacing Clin Electrophysiol.* 2008;31(3):283–289.

25. Scaglione M, Ebrilile E, Caponi D, et al. Single center experience of fluoroless AVNRT ablation guided by electroanatomic reconstruction in children and adolescents. *Pacing Clin Electrophysiol.* 2013;36(12):1460–1467.

26. Bigelow AM, Arnold BS, Padrutt GC, Clark JM. Non-fluoroscopic cardiac ablation of neonates with CHD. *Cardiol Young.* 2017;27(3):592–596.

27. Alvarez M, Tercedor L, Almansa I, et al. Safety and feasibility of catheter ablation for atrioventricular nodal re-entrant tachycardia without fluoroscopic guidance. *Heart Rhythm.* 2009;6(12):1714–1720.

28. Alvarez M, Tercedor L, Herrera N, et al. Cavitricuspid isthmus catheter ablation without the use of fluoroscopy as a first-line treatment. *J Cardiovasc Electrophysiol.* 2011;22(6):656–662.

29. Sommer P, Piorkowski C, Gaspar T, et al. MediGuide in supraventricular tachycardia: initial experience from a multicenter registry. *Europace.* 2013;15(9):1292–1297.

30. Jan M, Zizek D, Rupar K, et al. Fluoroless catheter ablation of various right and left sided supraventricular tachycardias in children and adolescents. *Int J Cardiovasc Imaging.* 2016;32(11):1609–1616.

31. Sanchez JM, Yanics MA, Wilson P, Doshi A, Kurian T, Pieper S. Fluoroless catheter ablation in adults: a single center experience. *J Interv Card Electrophysiol.* 2016;45(2):199–207.

32. Kozluk E, Rodkiewicz D, Piatkowska A, Opolski G. Safety and efficacy of cryoablation without the use of fluoroscopy. *Cardiol J.* 2018;25(3):327–332.

33. Kipp RJ, Boynton JR, Field ME, et al. Outcomes during intended fluoroscopy-free ablation in adults and children. *J Innov Card Rhythm Manag.* 2018;9:3305–3311.

34. Ruiz-Granell R, Morell-Cabello S, Ferrero-Del-Loma A, Garcia-Civera R. Atrialventricular node ablation and permanent ventricular pacemaker implantation without fluoroscopy: use of an electroanatomic navigation system. *J Cardiovasc Electrophysiol.* 2005;16(7):793–795.

35. Earley MJ, Showkathali R, Alzetai M, et al. Radiofrequency ablation of arrhythmias guided by non-fluoroscopic catheter location: a prospective randomized trial. *Eur Heart J.* 2006;27(10):1223–1229.

36. Gist K, Tiggges C, Smith G, Clark J. Learning curve for zero-fluoroscopy catheter ablation of AVNRT: early versus late experience. *Pacing Clin Electrophysiol.* 2011;34(3):264–268.

37. Stec S, Sledz J, Mazzj M, et al. Feasibility of implementation of a “simplified, no-X-ray, no-lead apron, two-catheter approach” for ablation of supraventricular arrhythmias in children and adults. *J Cardiovasc Electrophysiol.* 2014;25(8):866–874.

38. Fernandez-Gomez JM, Morina-Vazquez P, Morales Edel R, Venegas-Gamero J, Barba-Pichardo R, Carranza MH. Exclusion of fluoroscopy use in catheter ablation procedures: six years of experience at a single center. *J Cardiovasc Electrophysiol.* 2014;25(6):638–644.

39. Ceresnak SR, Pass RH, Group WPWI. The benefits of 3D mapping systems for ablation of WPW in children. *J Cardiovasc Electrophysiol.* 2015;26(10):E10–E11.

40. Giacciardi M, Del Rosso A, Guarnaccia V, et al. Near-zero x-ray in arrhythmia ablation using a 3-dimensional electroanatomic mapping system: a multicenter experience. *Heart Rhythm.* 2016;13(1):150–156.

41. Giacciardi M, Mascia G, Paolletti Perini A, Giomi A, Cartel S, Milli M. Long-term outcomes after “zero-X-ray” arrhythmia ablation. *J Interv Card Electrophysiol.* 2019;54(1):43–48.

42. Casella M, Dello Russo A, Pelargonio G, et al. Near-zero fluoroscopic exposure during catheter ablation of supraventricular arrhythmias: the NO-PARTY multicenter randomized trial. *Europace.* 2016;18(10):1565–1572.

43. Razminia M, Manankil MF, Eryazici F, et al. Nonfluoroscopic catheter ablation of cardiac arrhythmias in adults: feasibility, safety, and efficacy. *J Cardiovasc Electrophysiol.* 2012;23(10):1078–1086.

44. Papagiannis J, Avramidis D, Alexopoulos C, Kirvassilis G. Radiofrequency ablation of accessory pathways in children and congenital heart disease patients: impact of a nonfluoroscopic navigation system. *Pacing Clin Electrophysiol.* 2011;34(10):1288–1396.

45. Al-Ahmad A, Callans DJ, Hsia HH, Natale A, Oseroff O, Wang PJ. Hands-on Ablation: The Experts’ Approach. 2nd ed. Minneapolis, MN: Cardiotext Publishing; 2017.

46. Rolf S, John S, Gaspar T, et al. Catheter ablation of atrial fibrillation supported by novel nonfluoroscopic 4D navigation technology. *Heart Rhythm.* 2013;10(9):1293–1300.

47. Sommer P, Bertagnolli L, Kircher S, et al. Safety profile of near-zero fluoroscopy atrial fibrillation ablation with non-fluoroscopic catheter visualization: experience from 1000 consecutive procedures. *Europace.* 2018;20(12):1952–1958.

48. Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. *Europace.* 2018;20(1):e1–e140.

49. Reddy VY, Morales G, Ahmed H, et al. Catheter ablation of atrial fibrillation without the use of fluoroscopy. *Heart Rhythm.* 2010;7(11):1644–1653.

50. Lyam E, Tsygankov A, Abrahmanov A, et al. Nonfluoroscopic catheter ablation of paroxysmal atrial fibrillation. *Pacing Clin Electrophysiol.* 2018;41(6):611–619.

51. Ferguson JD, Helms A, Mangrum JM, et al. Catheter ablation of atrial fibrillation without fluoroscopy using intracardiac echocardiography and electroanatomical mapping. *Circ Arrhythm Electrophysiol.* 2009;2(6):611–619.

52. Haegeli LM, Stutz L, Mohsen M, et al. Feasibility of zero or near zero fluoroscopy during catheter ablation procedures. *Cardiol J.* 2019;26(3):226–232.

53. O'Brien B, Balmforth DC, Hunter RJ, Schilling RJ. Fluoroscopy-free AF ablation using transesophageal echocardiography and electroanatomical mapping technology. *J Interv Card Electrophysiol.* 2017;50(3):225–244.

54. Liu X, Palmer J. Outcomes of 200 consecutive, fluoroloe atrial fibrillation ablations using a new technique. *Pacing Clin Electrophysiol.* 2018;41(11):1404–1411.

55. Sadek MM, Ramirez FD, Nery PB, et al. Completely nonfluoroscopic catheter ablation of left atrial arrhythmias and ventricular tachycardia. *J Cardiovasc Electrophysiol.* 2019;30(1):78–88.

56. Cano O, Andres A, Osca J, et al. Safety and feasibility of a minimally fluoroscopic approach for ventricular tachycardia ablation in patients with structural heart disease: influence of the ventricular tachycardia substrate. *Circ Arrhythm Electrophysiol.* 2016;9(2):e003706.

57. Wang Y, Chen GZ, Yao Y, et al. Ablation of idiopathic ventricular arrhythmia using zero-fluoroscopy approach with equivalent efficacy and less fatigue: a multicenter comparative study. *Medicine (Baltimore).* 2017;96(6):e6080.

58. Bongiomi MG, Di Cori A, Soldati E, et al. Radiofrequency catheter ablation of atrioventricular nodal reciprocating tachycardia using intracardiac echocardiography in pregnancy. *Europace.* 2008;10(8):1018–1021.
59. Szumowski L, Szufladowicz E, Orczykowski M, et al. Ablation of severe drug-resistant tachyarrhythmia during pregnancy. *J Cardiovasc Electrophysiol*. 2010;21(8):877–882.

60. Ferguson JD, Helms A, Mangrum JM, DiMarco JP. Ablation of incessant left atrial tachycardia without fluoroscopy in a pregnant woman. *J Cardiovasc Electrophysiol*. 2011;22(3):346–349.

61. Manjaly ZR, Sachdev B, Webb T, Rajappan K. Ablation of arrhythmia in pregnancy can be done safely when necessary. *Eur J Obstet Gynecol Reprod Biol*. 2011;157(1):116–117.

62. Leiria TL, Martins Pires L, Lapa Kruse M, Glotz de Lima G. Supraventricular tachycardia and syncope during pregnancy: a case for catheter ablation without fluoroscopy. *Rev Port Cardiol*. 2014;33(12):805, e801–e805.

63. Zuberi Z, Silberbauer J, Murgatroyd F. Successful non-fluoroscopic radiofrequency ablation of incessant atrial tachycardia in a high risk twin pregnancy. *Indian Pacing Electrophysiol J*. 2014;14(1):26–31.

64. Omaygenc MO, Karaca IO, Guler E, et al. Radiofrequency catheter ablation of supraventricular tachycardia in pregnancy: ablation without fluoroscopic exposure. *Heart Rhythm*. 2015;12(5):1057–1061.

65. Bigelow AM, Crane SS, Khoury FR, Clark JM. Catheter ablation of supraventricular tachycardia without fluoroscopy during pregnancy. *Obstet Gynecol*. 2015;125(6):1338–1341.

66. Chen G, Sun G, Xu R, et al. Zero-fluoroscopy catheter ablation of severe drug-resistant arrhythmia guided by Ensite NavX system during pregnancy: two case reports and literature review. *Medicine (Baltimore)*. 2016;95(32):e4487.

67. Stec S, Krynski T, Baran J, Kulakowski P. “Rescue” ablation of electrical storm in arrhythmogenic right ventricular cardiomyopathy in pregnancy. *BMC Cardiovasc Disord*. 2013;13:58.

68. Kozluk E, Piatkowska A, Kiliszek M, et al. Catheter ablation of cardiac arrhythmias in pregnancy without fluoroscopy: a case control retrospective study. *Adv Clin Exp Med*. 2017;26(1):129–134.

69. Lin J, Adsit G, Barnett A, Tattersall M, Field ME, Wright J. Feasibility of ultrasound-guided vascular access during cardiac implantable device placement. *J Interpol Card Electrophysiol*. 2017;50(1):105–109.

70. Attanasio P, Mirdamadi M, Wielandts JY, et al. Safety and efficacy of applying a low-dose radiation fluoroscopy protocol in device implantations. *Europace*. 2017;19(8):1364–1368.

71. Attanasio P, Schreiber T, Parwani A, et al. The effect of an ultra-low frame rate and antiscatter grid-less radiation protocol for cardiac device implantations. *Pacing Clin Electrophysiol*. 2017;40(12):1380–1383.

72. Wannagat S, Loehr L, Lask S, et al. Implementation of a near-zero fluoroscopy approach in interventional electrophysiology: impact of operator experience. *J Interpol Card Electrophysiol*. 2018;51(3):215–220.